Table 3.
Multivariate Cox proportional hazards analysis of clinicopathologic and molecular prognostic variables in 240 patients with uveal melanoma
| Clinical variables incorporated into TNM stage | ||||
| Covariate | Regression Coefficient, β (SE) | Wald Statistic | P-value | Hazard Coefficient, Exp(b) (95% CI) |
| Gene expression profile | 1.5594 (0.3329) | 21.95 | 2.8 × 10−6 | 4.7559 (2.4768 to 9.1319) |
| PRAME status | 10061(0.2732) | 13.56 | 2.3 ×10−4 | 2.7349 (1.6009 to 4.6720) |
| TNM stage | 0.4136 (0.1221) | 11.47 | 7.1 × 10−4 | 1.5122 (1.1903 to 1.9213) |
| Male gendera | ||||
| Clinical variables analyzed separately | ||||
| Covariate | Regression Coefficient, β (SE) | Wald Statistic | P-value | Hazard Coefficient, Exp(b) (95% CI) |
| Gene expression profile | 1.6787 (0.3276) | 26.26 | 3.0 × 10−7 | 5.3484 (2.8195 to 10.1833) |
| Largest basal diameter | 0.1340 (0.0391) | 11.76 | 6.0 × 10−4 | 1.1434 (1.0591 to 1.2344) |
| PRAME status | 0.7989 (0.2784) | 8.23 | 0.0041 | 2.2230 (1.2881 to 3.8364) |
| Tumor thicknessa | ||||
| Ciliary body involvementa | ||||
| Male gendera | ||||
a
Excluded by the Cox multivariate model due to lack of significant independent prognostic value
Abbreviations: SE, standard error; CI, confidence interval; PRAME, preferentially expressed antigen in melanoma; TNM, Tumor-Node-Metastasis